Abstract
To review the role of Na,K-ATPase inhibitors in the pathogenesis of essential hypertension and hypertension associated with end-stage renal disease. MEDLINE search, 1966 to 1997. There is a suggestive physiologic and epidemiologic relationship between Na,K-ATPase inhibition and hypertension. However, clearance data cannot support the hypothesis that differential metabolism of this family of compounds explains the improved hypertensive control seen in patients on peritoneal dialysis compared to those on hemodialysis. As a result of the complex methodologies involved, it is unclear whether Na,K-ATPase inhibitors play a significant role in the hypertension of end-stage renal disease in general and peritoneal dialysis in particular.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
